BDBM305799 US10144734, Example 817::US10172845, Example 817::US10441581, Example 817::US10881652, Example 817::US11648243, Example 817

SMILES CCOc1cc(-c2ccc(nc2)N2CCC(Cc3ccccc3)(CC2)NC(=O)[C@H]2NCC[C@@H]2O)c2c(cnn2c1)C#N

InChI Key InChIKey=SVQMESFFCDFIDY-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 305799   

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 7nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 27nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 27nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 27nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 27nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 27nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 80nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 80nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 80nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 80nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305799(US10144734, Example 817 | US10172845, Example 817 ...)
Affinity DataIC50: 80nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent